Ninlaro
What Ninlaro is used for
Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Ninlaro
- Active substance
- ixazomib
- Disease area
- Multiple Myeloma
- Medicine group
- Antineoplastic agents
- ATC code
- L01XG03
- Marketing authorisation holder
- Takeda Pharma A/S
- Authorised in the EU since
- 2016
Official information
In the USA
Same active substance: Ninlaro
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ninlaro used for?
Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
What is the active substance in Ninlaro?
Ninlaro contains ixazomib.
Who makes Ninlaro?
The EU marketing authorisation holder is Takeda Pharma A/S.
Is Ninlaro an orphan medicine?
Yes. Ninlaro is designated an orphan medicine in the EU, for a rare disease (Multiple Myeloma).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU